<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136539</url>
  </required_header>
  <id_info>
    <org_study_id>98-222</org_study_id>
    <nct_id>NCT00136539</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer</brief_title>
  <official_title>Neoadjuvant Therapy With Herceptin and Taxol for Stage II/III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harold J. Burstein, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Vanguard Medical Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of administering
      Herceptin in combination with Taxol (paclitaxel) in the treatment of women with
      HER2-positive, early stage breast cancer prior to surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive Herceptin intravenously once weekly for 12 weeks, and Taxol
      intravenously every 3 weeks (week 1, week 4, week 7 and week 10).

      After 12 weeks of treatment, breast surgery will be performed (either a lumpectomy or a
      mastectomy).

      Once patients have recovered from the surgery, they will receive adriamycin and cytoxan every
      3 weeks for 4 cycles (12 weeks total).

      After Herceptin and Taxol therapy, tumor assessment will be performed along with an
      echocardiogram and mammogram.

      At the time of surgery, re-assessment of the tumor will be done.

      Blood work will be performed on day one of each chemotherapy cycle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the response of HER2-positive breast cancer to treatment with Herceptin and Taxol prior to surgery</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety of Herceptin and Taxol therapy followed by surgery and chemotherapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Given intravenously once weekly for 12 weeks prior to surgery.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxol</intervention_name>
    <description>Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>Given every three weeks for 12 weeks after surgery.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoxan</intervention_name>
    <description>Given every three weeks for 12 weeks after surgery.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have Stage II or III histologically diagnosed breast cancer

          -  Primary invasive breast cancers that overexpress the HER2/neu oncogene

          -  Age older than 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt; 1

          -  White blood cell (WBC) &gt; 4000/mm3

          -  Platelet count &gt; 100,000/mm3

          -  Bilirubin &lt; 1 x upper limit of normal (ULN)

          -  SGOT &lt; 1 x ULN

          -  Creatinine &lt; 1.5mg/dl

          -  Normal cardiac function and electrocardiogram (EKG) showing absence of ischemic
             changes or ventricular hypertrophy

        Exclusion Criteria:

          -  Excisional biopsy, sentinel node dissection or axillary node dissection.

          -  Prior history of breast cancer unless: diagnosed at least 2 years ago, present cancer
             is not in a previously irradiated breast, no prior therapy with anthracycline or
             taxane, no prior high-dose chemotherapy with stem cell or bone marrow transplant.

          -  Pregnant or breast-feeding women

          -  Uncontrolled infection

          -  Active or severe cardiovascular or pulmonary disease

          -  Peripheral neuropathy of any etiology that exceeds grade 1

          -  Prior history of malignancy treated without curative intent

          -  Uncontrolled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Burstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Harold J. Burstein, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Early Stage Breast Cancer</keyword>
  <keyword>HER2-positive</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Taxol</keyword>
  <keyword>Stage II Breast Cancer</keyword>
  <keyword>Stage III Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

